Literature DB >> 19050416

Reversible encephalopathy due to sulfasalazine.

Senem E Mut1, Gulnihal Kutlu, Serap Ucler, Abidin Erdal, Levent E Inan.   

Abstract

BACKGROUND: Sulfasalazine was devised by Swedish physician in the late 1930s in an attempt to treat "rheumatic polyarthritis." It is still a widely used anti-inflammatory agent especially in the treatment of rheumatologic disorders and inflammatory bowel diseases. Most of its side effects are benign, tolerable, and dose dependent, but less common severe systemic reactions have also been revealed. CASE
PRESENTATION: A 42-year-old woman diagnosed with rheumatoid arthritis was admitted to emergency service because of status epilepticus. Hepatitis and myelotoxicity were also present after laboratory investigations. The patient was on sulfasalazine treatment for 3 weeks with a daily dose of 2g. Cranial magnetic resonance imaging (MRI) revealed bilateral periventricular and subcortical lesions in the white matter of especially temporal and occipital regions. Cerebrospinal fluid (CSF) examination showed very high protein level (564 mg/L). After discontinuation of treatment, the clinical, CSF, and MRI findings regressed rapidly.
CONCLUSIONS: Side effects of sulfasalazine include neurotoxicity such as status epilepticus, cranial MRI lesions, and CSF abnormalities that were diagnosed in our patient after excluding other etiologic factors causing encephalitis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19050416     DOI: 10.1097/WNF.0b013e31817f125d

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  4 in total

1.  Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.

Authors:  Pierre A Robe; Didier H Martin; Minh T Nguyen-Khac; Maria Artesi; Manuel Deprez; Adelin Albert; Sophie Vanbelle; Stephane Califice; Markus Bredel; Vincent Bours
Journal:  BMC Cancer       Date:  2009-10-19       Impact factor: 4.430

Review 2.  Neurological disorders and inflammatory bowel diseases.

Authors:  Giovanni Casella; Gian Eugenio Tontini; Gabrio Bassotti; Luca Pastorelli; Vincenzo Villanacci; Luisa Spina; Vittorio Baldini; Maurizio Vecchi
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

3.  Quantification and Metabolite Identification of Sulfasalazine in Mouse Brain and Plasma Using Quadrupole-Time-of-Flight Mass Spectrometry.

Authors:  Jangmi Choi; Min-Ho Park; Seok-Ho Shin; Jin-Ju Byeon; Byeong Ill Lee; Yuri Park; Young G Shin
Journal:  Molecules       Date:  2021-02-22       Impact factor: 4.411

4.  Central-Variant Posterior Reversible Encephalopathy due to Sulfasalazine: A Case Report.

Authors:  Levent Ocek; Ufuk Sener; Burcu S Demirtas; Metin M Ozcelik; Ozgur Oztekin; Yasar Zorlu
Journal:  Med Princ Pract       Date:  2015-08-21       Impact factor: 1.927

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.